Daily Positive Signals: an angioedema pill, an enzyme map, and an AI that makes your calls
On this page
Listen to this brief · about 4 min, story text only
This edition: a daily pill that cuts hereditary swelling attacks by 83%; the first full map of an enzyme behind a rare brain-damaging disorder; and an AI agent that will make your phone calls for you. The thread: small, concrete steps that remove a daily burden.
In this edition · 3 signals
Signal 1 of 3 · Medicine
A daily pill cuts swelling attacks by 83%
Deucrictibant XR, a once-daily oral tablet for hereditary angioedema, cut monthly swelling attacks by 83% against a placebo in its pivotal Phase 3 trial, results announced November 12 and presented at the allergy specialists’ annual meeting on November 14 (Pharvaris, 2026). The global CHAPTER-3 trial randomized 85 participants, two to one, to the 40-milligram tablet or a placebo for 24 weeks, and the benefit appeared within the first week and held throughout the study (Pharvaris, 2026). In a post hoc analysis of participants with the most common forms of the disease, the attack rate was 87% lower on the drug (TechTimes, 2026). The drug blocks the bradykinin B2 receptor, the final step in the swelling cascade, which is why the trial could include all types of the disease, including the form with normal C1-inhibitor levels (Pharvaris, 2026).
Why it matters. Preventing these attacks today means injections, infusions, or a single oral drug that works by a different route. A daily pill with efficacy in the range of injectable therapies would turn a condition managed around needles into one managed around a morning tablet — if regulators agree.
Evidence status: Company-reported Phase 3 results (November 12, 2026), independently covered by TechTimes (November 14). Limits: investigational, not approved; adverse events were more common on the drug (76.4% vs 56.7%), including two Grade 3 liver enzyme elevations, one of which led to stopping treatment; the trial was small (85 participants); the company plans to file for approval in the first half of 2027.
Signal 2 of 3 · Medicine
A map of an enzyme opens a path to treating a rare disease
Researchers at Mount Sinai have produced the first detailed picture of the complete AASS enzyme, a protein whose failure drives glutaric aciduria type 1 (GA1), a rare inherited disorder that can cause irreversible brain damage (Mount Sinai, 2026). The team isolated the full human enzyme and mapped it with cryo-electron microscopy, then used biochemical experiments and computer simulations to show how it works (Mount Sinai, 2026). They found a hinge-like region where small structural changes have a large effect on the enzyme’s activity — a control switch that drug designers could target (MedicalXpress, 2026). The findings were published November 13 in Science Advances (Wu et al., 2026).
Why it matters. GA1 has no targeted treatment: toxic metabolites build up because the body cannot break down the amino acid lysine properly. Knowing the enzyme’s shape and its control switch gives researchers a concrete target to design inhibitors against, where before there was only the disease.
Evidence status: Peer-reviewed study in Science Advances (November 13, 2026), announced by Mount Sinai and independently covered by MedicalXpress. Limits: laboratory experiments only; the work is an early step, not a treatment or cure, and animal and human studies are still needed to show whether blocking AASS is safe and effective.
Signal 3 of 3 · AI
Your AI agent can now make the calls you dread
Meta’s AI agent Muse can now place phone calls to United States businesses on a user’s behalf, after testing the feature with a small group since September (TechCrunch, 2026). Meta’s chief AI officer, Alexandr Wang, announced the rollout on November 12, giving examples such as calls to a cable company, the DMV, or a restaurant without online reservations (TechCrunch, 2026). The feature is open to paying subscribers in the United States, with plans starting at $20 a month for 500 million tokens a week (TechCrunch, 2026; Gadgets360, 2026). Muse is not the first agent to offer this — a startup called Instinct and Google’s Gemini offer similar calling — but it brings the capability to a service with more than 10 million users (TechCrunch, 2026).
Why it matters. Phone trees and hold music are a small tax on everyone’s week, and an agent with infinite patience is well suited to paying it. The open question is on the other end of the line: receptionists often hang up as soon as they realize the caller is not human.
Evidence status: Company announcement (November 12, 2026), independently reported by TechCrunch and Gadgets360. Limits: paid subscribers in the United States only; Meta has not said how Muse identifies itself on calls; some businesses hang up on AI callers, so real-world reliability is unproven.
Editor’s note
Each signal today removes a recurring burden. A daily pill replaces injections for people who live with sudden, frightening swelling. A map of one enzyme turns a rare disease from untargetable to targetable, even if the drug is years away. And an agent that makes phone calls takes over the small chores nobody wants. None of these is a cure or a revolution. Each is a concrete step that gives someone their time, or their options, back.
That’s the edition — three signals, every claim verified against its sources. Browse past briefs · tomorrow’s lands at 07:15.
The Progress Brief, by email
Useful progress, without the hype
The daily Positive Signals brief and the weekly deep dive, by email. Evidence-checked, concise, no doom.
Free. One daily email, one weekly email. Unsubscribe anytime.
References
- Gadgets360. (2026, November 13). Meta Muse AI can now make phone calls to businesses for paid subscribers. https://www.gadgets360.com/ai/news/meta-muse-ai-outbound-calling-feature-rollout-12322765?from=app
- MedicalXpress. (2026, November 13). Mapping an enzyme offers clues to treating rare genetic disease. https://medicalxpress.com/news/2026-11-enzyme-clues-rare-genetic-disease.html
- Mount Sinai. (2026, November 13). Mapping an enzyme offers clues to treating rare genetic disease. https://www.mountsinai.org/about/newsroom/2026/mapping-an-enzyme-offers-clues-to-treating-rare-genetic-disease
- Pharvaris. (2026, November 12). Pharvaris presents clinical and real-world data at the ACAAI 2026 Annual Scientific Meeting. GlobeNewswire. https://www.globenewswire.com/news-release/2026/11/12/3401883/0/en/pharvaris-presents-clinical-and-real-world-data-at-the-acaai-2026-annual-scientific-meeting.html
- TechCrunch. (2026, November 12). Muse can now place calls to U.S. businesses — if you pay. https://techcrunch.com/2026/11/12/muse-can-now-place-calls-to-u-s-businesses-if-you-pay/
- TechTimes. (2026, November 14). Deucrictibant angioedema pill cuts attacks 83% against placebo in Phase 3, but liver signals appear. https://www.techtimes.com/articles/330728/20261114/deucrictibant-angioedema-pill-cuts-attacks-83-against-placebo-phase-3-liver-signals-appear.htm
- Wu, R., Khamrui, S., Dodatko, T., Xiang, Y., Golestanian, A., Pham, N. D., Kumar, K., Shi, Y., Osman, R., DeVita, R. J., Houten, S. M., & Lazarus, M. B. (2026). Structural and biochemical insight into allosteric regulation of the human 2-aminoadipic semialdehyde synthase. Science Advances. https://www.science.org/doi/10.1126/sciadv.aej2268







